Last reviewed · How we verify
ChAdOx1 nCoV-19 two dose + paracetamol
ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.
ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19. Used for COVID-19 prevention in adults (Phase 3).
At a glance
| Generic name | ChAdOx1 nCoV-19 two dose + paracetamol |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to carry genetic instructions for the SARS-CoV-2 spike protein into host cells. This triggers both cellular and humoral immune responses, generating T-cell and antibody-mediated immunity against the virus. Paracetamol is co-administered as an antipyretic/analgesic to manage common post-vaccination symptoms.
Approved indications
- COVID-19 prevention in adults (Phase 3)
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- A Study of a Candidate COVID-19 Vaccine (COV001) (PHASE1, PHASE2)
- A Study of a Candidate COVID-19 Vaccine (COV003) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChAdOx1 nCoV-19 two dose + paracetamol CI brief — competitive landscape report
- ChAdOx1 nCoV-19 two dose + paracetamol updates RSS · CI watch RSS
- University of Oxford portfolio CI